Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S

Docket No.
Op. Below
Argument
Dec 5, 2011
Tr.Aud.
Opinion
Vote
9-0
Author
Kagan
Term

Holding: A generic drug manufacturer may employ the counterclaim provision of the Hatch-Waxman Act to force correction of a use code that inaccurately describes the brand’s patent as covering a particular method of using a drug.

Judgment: Reversed and remanded, 9-0, in an opinion by Justice Kagan on April 17, 2012. Justice Sotomayor filed a concurring opinion.

SCOTUSblog Coverage

Briefs and Documents

CLICK HERE FOR FULL VERSION OF THIS STORY

Merits Briefs for Petitioners

Amicus Briefs Supporting Petitioners

Merits Briefs for the Respondents

Amicus Briefs Supporting the Respondents

[##CERT-STAGE##]

CLICK HERE FOR FULL VERSION OF THIS STORY